Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487837 | 0.84 | KMT2A (0.60) | DPP4LMNATSHRSMN1; SMN2KMT2A | |
| SCHEMBL20041938 | 0.83 | DPP4 (0.65) | DPP4LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL20248003 | 0.79 | DPP4 (0.86) | DPP4 | |
| SCHEMBL20041914 | 0.79 | DPP4 (1.00) | DPP4 | |
| SCHEMBL24250256 | 0.79 | DPP4 (1.00) | DPP4 | |
| SCHEMBL497449 | 0.78 | DPP4 (0.50) | DPP4LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL4469410 | 0.78 | DPP4 (0.55) | DPP4LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL4482398 | 0.77 | DPP4 (0.71) | DPP4LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL20041950 | 0.77 | DPP4 (0.63) | DPP4LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL3918944 | 0.76 | DPP4 (0.54) | DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305787-B1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-107709324-B | Xanthine derivatives | 江苏天士力帝益药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-106188058-B | Xanthine derivatives | 江苏天士力帝益药业有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20180162860-A1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3305787-A1 | XANTHINE DERIVATIVE | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162860-A1 | XANTHINE DERIVATIVE | XDH, CXCR1, CBR1 | DPP4 1294/4885LMNA 791/4885TSHR 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.